Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rifampicin Transport by OATP1B1 Variants.

Literature DB >> 32690641

Rifampicin Transport by OATP1B1 Variants.

Carlijn H C Litjens^1,2, Jeroen J M W van den Heuvel², Frans G M Russel², Rob E Aarnoutse³, Lindsey H M Te Brake³, Jan B Koenderink².

Abstract

Single nucleotide polymorphisms in the OATP1B1 transporter have been suggested to partially explain the large interindividual variation in rifampicin exposure. HEK293 cells overexpressing wild-type (WT) or OATP1B1 variants *1b, *4, *5, and *15 were used to determine the in vitro rifampicin intrinsic clearance. For OATP1B1*5 and *15, a 36% and 42% reduction in intrinsic clearance, respectively, compared to WT was found. We consider that these differences in intrinsic clearance most likely have minor clinical implications.

Entities: Chemical

Keywords: OATP1B1; SNP; drug transport; rifampicin

Mesh：

Substances：

Year: 2020 PMID： 32690641 PMCID： PMC7508598 DOI： 10.1128/AAC.00955-20

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

30 in total

1. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver.

Authors: C Reichel; B Gao; J Van Montfoort; V Cattori; C Rahner; B Hagenbuch; B Stieger; T Kamisako; P J Meier
Journal: Gastroenterology Date: 1999-09 Impact factor: 22.682

2. Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sex.

Authors: Bhagwat Prasad; Raymond Evers; Anshul Gupta; Cornelis E C A Hop; Laurent Salphati; Suneet Shukla; Suresh V Ambudkar; Jashvant D Unadkat
Journal: Drug Metab Dispos Date: 2013-10-11 Impact factor: 3.922

3. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.

Authors: Marc Weiner; Debra Benator; William Burman; Charles A Peloquin; Awal Khan; Andrew Vernon; Brenda Jones; Claudia Silva-Trigo; Zhen Zhao; Thomas Hodge
Journal: Clin Infect Dis Date: 2005-04-14 Impact factor: 9.079

4. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4.

Authors: Kathleen Köck; Brian C Ferslew; Ida Netterberg; Kyunghee Yang; Thomas J Urban; Peter W Swaan; Paul W Stewart; Kim L R Brouwer
Journal: Drug Metab Dispos Date: 2013-10-23 Impact factor: 3.922

5. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.

Authors: E van de Steeg; R Greupink; M Schreurs; I H G Nooijen; K C M Verhoeckx; R Hanemaaijer; D Ripken; M Monshouwer; M L H Vlaming; J DeGroot; M Verwei; F G M Russel; M T Huisman; H M Wortelboer
Journal: Drug Metab Dispos Date: 2012-12-17 Impact factor: 3.922

Review 6. Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors: Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal: Clin Pharmacokinet Date: 2003 Impact factor: 6.447

7. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver.

Authors: Stephan R Vavricka; Jessica Van Montfoort; Huy Riem Ha; Peter J Meier; Karin Fattinger
Journal: Hepatology Date: 2002-07 Impact factor: 17.425

8. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis.

Authors: K E Stott; H Pertinez; M G G Sturkenboom; M J Boeree; R Aarnoutse; G Ramachandran; A Requena-Méndez; C Peloquin; C F N Koegelenberg; J W C Alffenaar; R Ruslami; A Tostmann; S Swaminathan; H McIlleron; G Davies
Journal: J Antimicrob Chemother Date: 2018-09-01 Impact factor: 5.790